BAROSTIM NEO Hypertension Pivotal Trial
Completed · Not applicable · NCT01679132
Conditions: Uncontrolled Hypertension
At a glance
- Research payments reported, 2025
- $25,357
- U.S. investigators named
- 5
- Sites paid
- 3
- Planned or actual enrollment
- 10
About the trial
- Sponsor
- CVRx, Inc.
- Tested
- BAROSTIM NEO System and Medical Management (device)
- Dates
- Started 2013-04-12; completion 2025-07-23
- Results posted
- Not yet
The purpose of this clinical investigation (NCT01679132) is to assess the long-term safety and efficacy of the BAROSTIM NEO System in subjects currently participating in the BAROSTIM Hypertension Pivotal Trial (G120137).
From ClinicalTrials.gov, last updated 2026-09-11. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Cvrx, Inc. reported $25,357 in research payments for this study in 2025 (10 payments).
Products named: Barostim Neo System
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Marwan M. Bahu, M.D. Cardiac Electrophysiology · Phoenix, AZ
- Miguel F. Manzur, M.D. Vascular Surgery · Los Angeles, CA
- Fadi A. Matar, M.D. Interventional Cardiology · Tampa, FL
- Branislav Schifferdecker, M.D. Interventional Cardiology · Oklahoma City, OK
- German Larrain, MD Interventional Cardiology · Wausau, WI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Keck Hospital of Usc $17,460
- Wcg Irb $4,534
- Aspirus Research Institute $3,363
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.